Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test.
| Title: | Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. |
|---|---|
| Authors: | Refsgaard LK; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark.; Haubro K; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark.; Pickering DS; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark.; Stuart SA; School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Bristol, UK.; Robinson ES; School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, Bristol, UK.; Andreasen JT; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100, Copenhagen, Denmark. jta@sund.ku.dk. |
| Source: | Psychopharmacology [Psychopharmacology (Berl)] 2016 Oct; Vol. 233 (21-22), pp. 3763-3770. Date of Electronic Publication: 2016 Aug 30. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Berlin, New York, Springer-Verlag. |
| MeSH Terms: | Adrenergic alpha-2 Receptor Antagonists/*pharmacology ; Affect/*drug effects ; Antidepressive Agents/*pharmacology ; Behavior, Animal/*drug effects ; Duloxetine Hydrochloride/*pharmacology ; Idazoxan/*pharmacology ; Piperazines/*pharmacology ; Sertraline/*pharmacology ; Sulfides/*pharmacology; Selective Serotonin Reuptake Inhibitors/pharmacology ; Animals ; Male ; Rats ; Rats, Sprague-Dawley ; Reward ; Vortioxetine |
| Abstract: | Rationale: Affective biases seemingly play a crucial role for the onset and development of depression. Acute treatment with monoamine-based antidepressants positively influences emotional processing, and an early correction of biases likely results in repeated positive experiences that ultimately lead to improved mood.; Objectives: Using two conventional antidepressants, sertraline and duloxetine, we aimed to forward the characterization of a newly developed affective bias test (ABT) for rats. Further, we examined the effect of vortioxetine, a recently approved antidepressant, and the α2 adrenoceptor antagonist idazoxan on affective biases.; Methods: Sprague Dawley rats were tested in an affective bias test using a fully balanced within-subject study design. Rats learned to associate two different digging substrates with a reward during six reward-pairing days. The absolute value of the rewards was identical, but the affective state at the time of learning induces a positive or negative bias towards the treatment-paired digging substrate at recall. The choice bias between the two digging substrates at recall represents the affective bias. Sertraline (1, 3 and 10 mg/kg), duloxetine (1, 3 and 10 mg/kg), vortioxetine (1, 3 and 10 mg/kg) and idazoxan (3 and 10 mg/kg) were tested in the ABT.; Results and Conclusions: All four drugs, regardless of their mechanism of action, induced a positive affective bias in the ABT, although the overall effect of treatment was not statistically significant for sertraline and duloxetine. The largest effects were induced by vortioxetine and idazoxan, both of which caused significant positive biases at all tested doses. |
| References: | J Affect Disord. 1999 Dec;56(2-3):237-43. (PMID: 10701483); Am J Psychiatry. 2004 Jul;161(7):1256-63. (PMID: 15229059); Schizophr Res. 2009 Feb;107(2-3):206-12. (PMID: 18789844); Neuropsychopharmacology. 2013 Aug;38(9):1625-35. (PMID: 23503126); Am J Psychiatry. 2009 Oct;166(10):1178-84. (PMID: 19755572); J Psychopharmacol. 2012 Nov;26(11):1408-16. (PMID: 22495621); Am J Psychiatry. 2003 May;160(5):990-2. (PMID: 12727705); J Abnorm Psychol. 2004 Feb;113(1):121-35. (PMID: 14992665); J Affect Disord. 2006 Apr;91(2-3):243-50. (PMID: 16499971); Int Clin Psychopharmacol. 2003 Jan;18(1):9-14. (PMID: 12490769); Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. (PMID: 23076926); Neuropsychopharmacology. 2003 Jan;28(1):148-52. (PMID: 12496951); Xenobiotica. 1988 May;18(5):519-32. (PMID: 2899932); Neuropsychopharmacology. 2015 Aug;40(9):2165-74. (PMID: 25740288); Psychopharmacology (Berl). 1995 Aug;120(4):409-17. (PMID: 8539321); J Psychopharmacol. 2000 Jun;14(2):114-38. (PMID: 10890307); Nat Rev Neurosci. 2011 Jul 06;12 (8):467-77. (PMID: 21731066); Psychiatry Res. 1992 Jun;42(3):241-51. (PMID: 1496056); J Neurochem. 1997 Dec;69(6):2616-9. (PMID: 9375697); Psychopharmacology (Berl). 2008 Sep;199(4):495-502. (PMID: 18575851); Behav Brain Res. 2004 Dec 6;155(2):275-82. (PMID: 15364487); Pharmacol Biochem Behav. 2013 Apr;105:41-50. (PMID: 23380522); J Psychopharmacol. 2004 Sep;18(3):395-403. (PMID: 15358984); Biol Psychol. 2002 Sep;60(2-3):79-90. (PMID: 12270585); Arch Gen Psychiatry. 1989 Oct;46(10):958-9. (PMID: 2572209); Neurosci Biobehav Rev. 2012 Nov;36(10):2214-25. (PMID: 22910678); J Psychiatr Res. 2003 Mar-Apr;37(2):99-108. (PMID: 12842163); Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600. (PMID: 21767441); Depress Res Treat. 2014;2014:627863. (PMID: 24563781); Neuropsychopharmacology. 2015 Jul;40(8):2025-37. (PMID: 25687662); Biochem Pharmacol. 1984 Aug 15;33(16):2553-7. (PMID: 6147143); J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. (PMID: 22171087); Curr Top Behav Neurosci. 2013;14:209-22. (PMID: 22566081); Neuroscience. 2015 Mar 19;289:262-9. (PMID: 25595980); Psychopharmacology (Berl). 2009 May;203(4):685-91. (PMID: 19031070); Br J Psychiatry. 2009 Aug;195(2):102-8. (PMID: 19648538); J Psychiatr Res. 2009 Jun;43(9):855-63. (PMID: 19128810); Life Sci. 1993;52(12):1023-9. (PMID: 8445992); Biol Psychiatry. 2005 May 15;57(10):1089-96. (PMID: 15866547); Am J Physiol. 1991 Jan;260(1 Pt 2):R142-7. (PMID: 1847020); Br J Psychiatry. 2009 Jun;194(6):535-40. (PMID: 19478294); Curr Med Res Opin. 2014 Dec;30(12):2589-606. (PMID: 25249164); Am J Psychiatry. 2007 Jun;164(6):900-9. (PMID: 17541049); J Clin Psychiatry. 2002 May;63(5):396-402. (PMID: 12019663); Neuropharmacology. 2013 Oct;73:147-59. (PMID: 23721744); Br J Pharmacol. 1993 Jul;109(3):655-60. (PMID: 8102934); J Pharmacol Exp Ther. 2011 Aug;338(2):605-14. (PMID: 21558435); Drug Metab Dispos. 1989 Sep-Oct;17(5):542-50. (PMID: 2573498); Behav Brain Res. 2011 Jun 20;220(1):83-90. (PMID: 21277905); Int Clin Psychopharmacol. 2012 Jul;27(4):215-23. (PMID: 22572889); Br J Pharmacol. 2014 Oct;171(20):4524-38. (PMID: 24467454); Int J Geriatr Psychiatry. 2012 Aug;27(8):777-84. (PMID: 21919060); Neuropsychopharmacology. 1995 Jul;12(4):287-95. (PMID: 7576005); Psychol Med. 2007 Sep;37(9):1281-91. (PMID: 17493298) |
| Grant Information: | MR/L011212/1 United Kingdom MRC_ Medical Research Council |
| Contributed Indexing: | Keywords: Affective bias*; Antidepressant*; Cognition*; Depression*; Emotional processing* |
| Substance Nomenclature: | 0 (Adrenergic alpha-2 Receptor Antagonists); 0 (Antidepressive Agents); 9044SC542W (Duloxetine Hydrochloride); Y310PA316B (Idazoxan); 0 (Piperazines); 0 (Selective Serotonin Reuptake Inhibitors); QUC7NX6WMB (Sertraline); 0 (Sulfides); 3O2K1S3WQV (Vortioxetine) |
| Entry Date(s): | Date Created: 20160831 Date Completed: 20171116 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| DOI: | 10.1007/s00213-016-4407-6 |
| PMID: | 27572627 |
| Database: | MEDLINE |
Journal Article